Therefore, it is urgently needed to establish highly effective combination therapy, incorporating PD-1/PD-L1 blockade drugs with other potent partner agents to maximize the clinical benefits for patients with pancreatic cancer.5 19 20. The gene discussed is CD274; the disease is familial pancreatic carcinoma.